Antibody-Negative Nivolumab-Induced Autoimmune Encephalitis: A Case Report and Review of Seronegative Presentations.
증례보고
1/5 보강
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but can provoke immune-related neurological complications, including autoimmune encephalitis (AIE).
APA
Hamza M, Randolph H, Thebault S (2026). Antibody-Negative Nivolumab-Induced Autoimmune Encephalitis: A Case Report and Review of Seronegative Presentations.. Cureus, 18(2), e102834. https://doi.org/10.7759/cureus.102834
MLA
Hamza M, et al.. "Antibody-Negative Nivolumab-Induced Autoimmune Encephalitis: A Case Report and Review of Seronegative Presentations.." Cureus, vol. 18, no. 2, 2026, pp. e102834.
PMID
41788085 ↗
Abstract 한글 요약
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but can provoke immune-related neurological complications, including autoimmune encephalitis (AIE). We report a 70-year-old woman who developed AIE after 11 months of adjuvant nivolumab for melanoma. Serial cerebrospinal fluid (CSF) studies revealed a lymphocytic pleocytosis and elevated protein that improved with corticosteroids, intravenous immunoglobulin (IVIG), and rituximab. Magnetic resonance imaging (MRI) showed evolving bilateral thalamic and periventricular T2/FLAIR (fluid-attenuated inversion recovery) hyperintensities. CSF and serum were negative for paraneoplastic and antineuronal antibodies. Altogether, this case illustrates a late-onset, antibody-negative form of ICI-associated AIE. We also provide a focused review of ICI-associated seronegative AIE presentations, including epidemiology, clinical features, diagnostic approach, management, and prognosis. This report underscores the need for sustained vigilance for AIE throughout the course of ICI therapy and highlights serial CSF cell counts as a useful biomarker for diagnostic support and treatment monitoring.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase II Study of Durvalumab, Doxorubicin, and Ifosfamide in Recurrent and/or Metastatic Pulmonary Sarcomatoid Carcinoma (KCSG LU-19-24).
- SLC2A1 tumour-associated macrophages spatially control CD8 T cell function and drive resistance to immunotherapy in non-small-cell lung cancer.
- Distribution of Immune Cells in Tumor Microenvironment Correlates With Checkpoint Inhibitor Response in Nasopharyngeal Carcinoma: A Multiregional Study.
- Immune Checkpoint Inhibitors for Recurrent Hepatocellular Carcinoma After Liver Transplantation: Safety Under an Immunosuppression-Preserving Strategy.
- Enhanced efficacy and long-term survival with SBRT plus PD-1 inhibitors versus SBRT alone in unresectable HCC: a multicenter PSM study.
- Advances in IL-15-Based Cancer Immunotherapy and Divergent Immunological Effects of IL-2 and IL-15 Signaling via the Shared IL-2Rβγ Receptor.